恩替卡韦、富马酸替诺福韦地索普西和替诺福韦艾拉酚胺在

StephenW

恩替卡韦、富马酸替诺福韦地索普西和替诺福韦艾拉酚胺在初治乙型肝炎患者中的疗效

    Hye Yeon Chon、Sang Hoon Ahn、Yoon Jun Kim、Jung-Hwan Yoon、Jeong-Hoon Lee、Dong Hyun Sinn 和 Seung Up Kim

Hepatology International 第 15 卷，第 1328-1336 页（2021）引用本文

    129 次访问

    指标详情

抽象的
背景和目标

慢性乙型肝炎 (CHB) 的抗病毒药物可降低发生肝细胞癌 (HCC) 的风险。恩替卡韦 (ETV)、富马酸替诺福韦地索普西 (TDF) 和替诺福韦艾拉酚胺 (TAF) 在 CHB 患者中的结果进行了比较。
方法

2017 年至 2019 年期间，从韩国三所高等教育机构招募了接受 ETV、TDF 和 TAF 治疗的初治 CHB 患者。在三匹配前后使用 Kaplan-Meier 分析计算和比较 HCC 和原位肝移植 (OLT) 的累积发生率或死亡率。
结果

在招募的 2082 名患者中，43 名患者发生了 HCC，而 66 名患者发生了 OLT 或死亡。在三匹配之前，接受三种抗病毒药物治疗的患者的 HCC 累积发生率在统计学上相似（p = 0.340）。然而，接受 ETV 或 TDF 治疗的患者的 OLT 或死亡率发展的累积概率显着高于三配前 TAF 患者（所有 p < 0.05）。在多变量分析中，男性 [风险比 (HR) 2.990] 和年龄较大 (HR 1.044) 与 HCC 发展风险增加独立相关，而较高的血小板计数 (HR 0.993) 与风险降低独立相关（所有 p < 0.05)。抗病毒药物的类型对 HCC 和 OLT 的风险或死亡率发展没有显着影响（所有 p > 0.05）。三匹配后，根据抗病毒药物，HCC 和 OLT 的累积概率或死亡率没有显着差异（所有 p > 0.05）。
结论

ETV、TDF 和 TAF 对 HCC 和 OLT 风险或死亡率的结果在未接受过治疗的 CHB 患者中具有统计学意义。

StephenW

Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients

    Hye Yeon Chon, Sang Hoon Ahn, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Dong Hyun Sinn & Seung Up Kim

Hepatology International volume 15, pages 1328–1336 (2021)Cite this article

    129 Accesses

    Metrics details

Abstract
Background and aims

Antiviral agents for chronic hepatitis B (CHB) reduced the risk of hepatocellular carcinoma (HCC) development. The outcomes of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) were compared in patients with CHB.
Methods

Between 2017 and 2019, treatment-naïve patients with CHB treated with ETV, TDF, and TAF were recruited from three Korean tertiary institutes. The cumulative incidences of HCC and orthotopic liver transplantation (OLT) or mortality were calculated and compared using Kaplan–Meier analysis before and after trimatch.
Results

Among recruited 2082 patients, 43 patients developed HCC, whereas 66 developed OLT or mortality. Before trimatch, the cumulative incidence of HCC was statistically similar among patients treated with three antiviral agents (p = 0.340). However, the cumulative probability of OLT or mortality development in patients treated with ETV or TDF was significantly higher than that of patients with TAF before trimatch (all p < 0.05). On multivariate analysis, male sex [hazard ratio (HR) 2.990] and older age (HR 1.044) were independently associated with an increased risk of HCC development, whereas higher platelet count (HR 0.993) was independently associated with a decreased risk (all p < 0.05). The type of antiviral agents did not significantly influence the risk of HCC and OLT or mortality development (all p > 0.05). After trimatch, no significant difference in the cumulative probability for HCC and OLT or mortality according to antiviral agents was found (all p > 0.05).
Conclusions

The outcomes of ETV, TDF, and TAF on the risk of HCC and OLT or mortality were statistically similar in treatment-naïve patients with CHB.